Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danjin Shugan Capsule (丹金舒肝胶囊) is a Traditional Chinese Medicine (TCM) formulation primarily utilized in China for the treatment of chronic liver and gallbladder diseases. The preparation typically contains a combination of herbal extracts, including *Salvia miltiorrhiza* (Danshen), *Curcuma wenyujin* (Yujin), *Lysimachia christinae* (Jinqiancao), and *Galli Gigerii Endothelium Corneum* (Jineijin). It is clinically indicated for conditions such as chronic hepatitis B and C, liver fibrosis, and cirrhosis, where it is intended to soothe the liver, resolve blood stasis, and promote liver regeneration. The drug is currently being evaluated in clinical trials, such as those conducted by the First Hospital of Hebei Medical University, to further establish its efficacy in reversing hepatic fibrosis and supporting liver regeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on danjin shugan capsule.